
Sign up to save your podcasts
Or


CEO Adrian Gottschalk describes chromatin regulation at a high level, and walks us through the Lilly partnership targeting SMARCA2, and Foghorn's independent programs targeting CBP, EP300, and ARID1B.
By BiotechTV4.3
66 ratings
CEO Adrian Gottschalk describes chromatin regulation at a high level, and walks us through the Lilly partnership targeting SMARCA2, and Foghorn's independent programs targeting CBP, EP300, and ARID1B.

3,222 Listeners

1,910 Listeners

124 Listeners

324 Listeners

61 Listeners

9,957 Listeners

86 Listeners

34 Listeners

353 Listeners

19 Listeners

60 Listeners

512 Listeners

41 Listeners

0 Listeners

4 Listeners

2 Listeners

6 Listeners

48 Listeners